MannKind (MNKD) Reports Positive Data From Two Phase 1 Studies
More News related to FDA
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
MannKind Corporation said results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
MannKind's data is being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting.
“MKC1106-MT and MKC1106-PP met the primary end-points of both trials and, in addition, showed early evidence of clinical benefit, which marks an important step forward for MannKind’s oncology portfolio,” said Peter Richardson, MRCP, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. “These encouraging results set the stage to move into phase 2 trials with these innovative, targeted therapies, which represent the cornerstone of our cancer immunotherapy program."
Stocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
